Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

IL-33 signaling in severe allergy
May 2017
SHARING OPTIONS:

SAN DIEGO—Biotechnology company AnaptysBio Inc. has reported that its collaborators at the Benaroya Research Institute at Virginia Mason (BRI) recently presented a translational research study at the AAAAI 2017 Annual Meeting. The study evaluated the biology of TH2A cells, a subset of T cells found in elevated numbers in patients with peanut allergies. These cells display increased sensitivity to IL-33 signaling due to higher expression of that cytokine’s receptor, and when stimulated with IL-33, TH2A cells express much higher levels of effector cytokines IL-4, IL-5 and IL-13, which are thought to be linked with severe peanut allergy. The study highlighted IL-33 as a key checkpoint for allergic responses and IL-33 blocade as a potential approach for reducing cytokine expression in cases of severe peanut allergy. AnaptysBio is advancing ANB020, its proprietary anti-IL-33 antibody as a treatment for severe adult peanut allergy, and is now enrolling patients in a Phase 2a trial.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.